Vaginal Cancer - Pipeline Review, Q4 2010

Date: December 1, 2010
Pages: 26
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: V5834669D73EN
Leaflet:

Download PDF Leaflet

Vaginal Cancer - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Vaginal Cancer Pipeline Review, Q4 2010”, provides an overview of the Vaginal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Vaginal Cancer , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Cancer . “Vaginal Cancer -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • A snapshot of the global therapeutic scenario for Vaginal Cancer   .
  • A review of the Vaginal Cancer    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Vaginal Cancer    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • A snapshot of the global therapeutic scenario for Vaginal Cancer   .
  • A review of the Vaginal Cancer    products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Vaginal Cancer    pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Introduction
Global Markets Direct Report Coverage
Vaginal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Vaginal Cancer
Vaginal Cancer Therapeutics under Development by Companies
Vaginal Cancer Therapeutics under Investigation by Universities/Institutes
Companies Involved in Vaginal Cancer Therapeutics Development
Merck & Co., Inc.
Universities/Institutes Involved in Vaginal Cancer Therapeutics Development
Vaginal Cancer Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
HPV vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
V503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 2

LIST OF TABLES

Number of Products Under Development for Vaginal Cancer, 2010
Products under Development for Vaginal Cancer – Comparative Analysis, 2010
Merck & Co., Inc., 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Discontinued Products 24

LIST OF FIGURES

Number of Products under Development for Vaginal Cancer, 2010
Products under Development for Vaginal Cancer – Comparative Analysis, 2010
Products under Development by Companies, 2010
Products under Investigation by Universities/Institutes, 2010
Assessment by Monotherapy Products, 2010
Assessment by Combination Products, 2010
Assessment by Route of Administration, 2010
Assessment by Stage and Route of Administration, 2010
Assessment by Molecule Type, 2010
Assessment by Stage and Molecule Type, 2010 20
Vaginal Cancer - Pipeline Review, Q2 2011 US$ 450.00 Apr, 2011 · 41 pages
Vaginal Cancer – Pipeline Review, H2 2012 US$ 1,800.00 Nov, 2012 · 33 pages
Thyroid Cancer - Pipeline Review, Q2 2011 US$ 450.00 Apr, 2011 · 141 pages
Pancreatic Cancer - Pipeline Review, Q2 2011 US$ 450.00 May, 2011 · 371 pages
Medullary Thyroid Cancer - Pipeline Review, Q3 2011 US$ 450.00 Jul, 2011 · 41 pages

Ask Your Question

Vaginal Cancer - Pipeline Review, Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: